Depression is common in end-stage renal disease (ESRD) patients and has a negative effect on the quality of life, functional ability, and mortality, with a prevalence rate as high as 20-25%. However, it is hard to use anti-depressant due to the safety issue, and there has been little data so far particularly in terms of randomized clinical trials. Here, we investigate the effect of cognitive-behavioral group therapy for enhancing mental health and quality of life in patients with ESRD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
15
Seoul National University Boramae Hospital
Seoul, South Korea
Beck Depression Inventory-II (BDI-II) score
Time frame: 3 months
Secondary assessment tools for depression,anxiety, and quality of life
Hamilton Depression Rating Scale (HAMD-17): assessment for depressive mood
Time frame: 3 months
Secondary assessment tools for depression,anxiety, and quality of life
Beck Anxiety Inventory (BAI)
Time frame: 3 months
Secondary assessment tools for depression,anxiety, and quality of life
The Perceived Stress Scale
Time frame: 3 months
Secondary assessment tools for depression,anxiety, and quality of life
KD-QOL: quality of life related with kidney disease
Time frame: 3 months
Secondary assessment tools for depression,anxiety, and quality of life
WHOQOL\_BREF: overall quality of life
Time frame: 3 months
Secondary assessment tools for depression,anxiety, and quality of life
Temperament and Character Inventory (TCI)
Time frame: 3 months
Secondary assessment tools for depression,anxiety, and quality of life
Diagnosis of major depressive disorder by DSM-IV
Time frame: 3 months
Secondary assessment tools for depression,anxiety, and quality of life
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Biomarker related with depression: serotonin level and etc.
Time frame: 3 months
Secondary assessment tools for depression,anxiety, and quality of life
Additional anti-depressant use after trial
Time frame: 3 months